Protocolo del estudio MEDyGEN-2024: evaluación de la utilización de medicamentos antihipertensivos según sexo en farmacias comunitarias.

Saved in:

Bibliographic Details
Title:	Protocolo del estudio MEDyGEN-2024: evaluación de la utilización de medicamentos antihipertensivos según sexo en farmacias comunitarias.
Alternate Title:	Protocol of the medygen-2024 study: assessment of antihypertensive medication use by sex in community pharmacies.
Authors:	Armas, Daida Alberto¹ daida.alar@gmail.com, Climent Catalá, María Teresa², Tomás, María Gil³, Díaz Poveda, Ana³, Ibáñez Jaime, María Dolores⁴, Hernández García, Verónica¹
Source:	Farmacéuticos Comunitarios. ene2026, Vol. 18 Issue 1, p1-14. 14p.
Subjects:	HYPERTENSION, GENDER differences (Psychology), DRUG side effects, MEDICATION errors, MEDICATION therapy management, CARDIOVASCULAR diseases, DRUGSTORES, ANTIHYPERTENSIVE agents
Abstract (English):	Hypertension is a chronic condition with a high prevalence in the adult population, with differences in response to treatment and the occurrence of adverse effects between men and women. Despite the available evidence, current clinical guidelines do not include specific recommendations differentiated by sex. From the community pharmacy perspective, it is important to explore how a structured pharmaceutical intervention, based on the detection of medication-related problems (MRPs), particularly adverse drug reactions (ADRs), and negative medication outcomes (NMOs) and, can contribute to improving the safety and effectiveness of antihypertensive treatment, considering gender as a clinical criterion. An experimental, multicentre, pre-post study was proposed in community pharmacies in different Spanish autonomous communities that are members of SEFAC. Patients who met the inclusion criteria were offered the opportunity to participate in the study at the time of dispensing. After signing the informed consent form, an initial interview was conducted to collect clinical variables, knowledge of treatment, therapeutic adherence, blood pressure and ADRs. Subsequently, an individualised pharmaceutical intervention was carried out with health recommendations and referral to the primary care physician for dosage adjustments, if necessary and when PRMs and/or ADRs were identified. After three months, the interview was repeated with the same parameters to assess the impact of the intervention. This study is expected to provide evidence on the importance of integrating the sex into the pharmaceutical approach to hypertension and reinforce the role of community pharmacists in cardiovascular health. [ABSTRACT FROM AUTHOR]
Abstract (Spanish):	La hipertensión arterial (HTA) es una patología crónica de alta prevalencia en la población adulta que presenta diferencias en la respuesta al tratamiento y en la aparición de efectos adversos entre hombres y mujeres. A pesar de la evidencia disponible, las guías clínicas actuales no contemplan recomendaciones específicas diferenciadas por sexo. Desde la farmacia comunitaria, resulta relevante explorar cómo una intervención farmacéutica (IF) estructurada, basada en la detección de problemas relacionados con los medicamentos (PRM), especialmente los efectos adversos (RAM), y los resultados negativos asociados a la medicación (RNM) puede contribuir a mejorar la seguridad y efectividad del tratamiento antihipertensivo considerando la variable sexo como criterio clínico. Se planteó un estudio experimental, multicéntrico y pre-post en farmacias comunitarias de distintas comunidades autónomas españolas, socias de SEFAC. A los pacientes que cumplían los criterios de inclusión se les ofreció participar en el estudio en el momento de la dispensación. Tras firmar el consentimiento informado, se realizó una entrevista inicial para recoger variables clínicas, conocimiento del tratamiento, adherencia terapéutica, presión arterial y RAM. Posteriormente, se efectuó una intervención farmacéutica individualizada con recomendaciones sanitarias y derivación al médico de atención primaria para ajustes posológicos, en caso necesario y cuando se identificaron PRM y/o RNM. A los tres meses, se repitió la entrevista con los mismos parámetros para valorar el impacto de la intervención. Se espera que este estudio aporte evidencia sobre la importancia de integrar la perspectiva de género en el abordaje farmacéutico de la hipertensión y refuerce el papel del farmacéutico comunitario en la salud cardiovascular. [ABSTRACT FROM AUTHOR]
	Copyright of Farmacéuticos Comunitarios is the property of Sociedad Espanola de Farmacia Familiar y Comunitaria and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	MedicLatina

Description
Abstract:	Hypertension is a chronic condition with a high prevalence in the adult population, with differences in response to treatment and the occurrence of adverse effects between men and women. Despite the available evidence, current clinical guidelines do not include specific recommendations differentiated by sex. From the community pharmacy perspective, it is important to explore how a structured pharmaceutical intervention, based on the detection of medication-related problems (MRPs), particularly adverse drug reactions (ADRs), and negative medication outcomes (NMOs) and, can contribute to improving the safety and effectiveness of antihypertensive treatment, considering gender as a clinical criterion. An experimental, multicentre, pre-post study was proposed in community pharmacies in different Spanish autonomous communities that are members of SEFAC. Patients who met the inclusion criteria were offered the opportunity to participate in the study at the time of dispensing. After signing the informed consent form, an initial interview was conducted to collect clinical variables, knowledge of treatment, therapeutic adherence, blood pressure and ADRs. Subsequently, an individualised pharmaceutical intervention was carried out with health recommendations and referral to the primary care physician for dosage adjustments, if necessary and when PRMs and/or ADRs were identified. After three months, the interview was repeated with the same parameters to assess the impact of the intervention. This study is expected to provide evidence on the importance of integrating the sex into the pharmaceutical approach to hypertension and reinforce the role of community pharmacists in cardiovascular health. [ABSTRACT FROM AUTHOR]
ISSN:	18858619
DOI:	10.33620/FC.2173-9218.(2026).04